G1 Therapeutics Management
Management criteria checks 2/4
G1 Therapeutics' CEO is Jack Bailey, appointed in Jan 2021, has a tenure of 3.33 years. total yearly compensation is $3.25M, comprised of 24.5% salary and 75.5% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth $600.38K. The average tenure of the management team and the board of directors is 3.3 years and 5.7 years respectively.
Key information
Jack Bailey
Chief executive officer
US$3.3m
Total compensation
| CEO salary percentage | 24.5% |
| CEO tenure | 3.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.3yrs |
| Board average tenure | 5.7yrs |
Recent management updates
Recent updates
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
Mar 22Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge
Feb 27
Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?
Feb 06G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry
Jan 04Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
Jun 08New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)
May 08The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts
Nov 04G1 Therapeutics: Catalysts Stacking
Oct 20G1 Therapeutics: Building A Franchise
Sep 29Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)
Aug 04G1 Therapeutics Q2 2022 Earnings Preview
Aug 02G1 Therapeutics: Take Advantage Of The November Data
Jul 22G1 Therapeutics granted regulatory nod for cancer therapy in China
Jul 13G1 Therapeutics: Needs To Expand Labels And Commercialize Better
Apr 27Health Check: How Prudently Does G1 Therapeutics (NASDAQ:GTHX) Use Debt?
Apr 19G1 Therapeutics: Biotech With FDA Approved Drug Plus Additional Potential
Feb 08G1 Therapeutics (NASDAQ:GTHX) Has Debt But No Earnings; Should You Worry?
Dec 07G1 Therapeutics: Market May Be Terribly Underestimating This Company
Nov 20G1 Therapeutics (NASDAQ:GTHX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 03G1 Therapeutics: Poised To Deliver A Blockbuster
Aug 28G1 Therapeutics: Pullback Presents Opportunity
Aug 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$31m |
| Dec 31 2023 | US$3m | US$795k | -US$48m |
| Sep 30 2023 | n/a | n/a | -US$71m |
| Jun 30 2023 | n/a | n/a | -US$78m |
| Mar 31 2023 | n/a | n/a | -US$126m |
| Dec 31 2022 | US$3m | US$764k | -US$148m |
| Sep 30 2022 | n/a | n/a | -US$154m |
| Jun 30 2022 | n/a | n/a | -US$171m |
| Mar 31 2022 | n/a | n/a | -US$171m |
| Dec 31 2021 | US$9m | US$735k | -US$148m |
| Sep 30 2021 | n/a | n/a | -US$134m |
| Jun 30 2021 | n/a | n/a | -US$103m |
| Mar 31 2021 | n/a | n/a | -US$95m |
| Dec 31 2020 | US$2m | n/a | -US$99m |
Compensation vs Market: Jack's total compensation ($USD3.25M) is above average for companies of similar size in the US market ($USD1.62M).
Compensation vs Earnings: Jack's compensation has increased whilst the company is unprofitable.
CEO
Jack Bailey (58 yo)
3.3yrs
Tenure
US$3,250,658
Compensation
Mr. John E. Bailey, also known as Jack, Jr. has been Director at G1 Therapeutics, Inc. since March 12, 2020. He serves as President and Chief Executive Officer at G1 Therapeutics Inc. since January 1, 2021...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.3yrs | US$3.25m | 0.28% $ 600.4k | |
| Chief Medical Officer | 9.8yrs | US$1.11m | 0.14% $ 311.7k | |
| Chief Business Officer | 4.8yrs | US$1.17m | 0.027% $ 57.3k | |
| Chief Financial Officer | 1.2yrs | no data | 0.018% $ 38.9k | |
| Chief Operating Officer | 5.3yrs | US$2.75m | 0.018% $ 37.8k | |
| Vice President of Investor Relations & Corporate Communications | 3.3yrs | no data | no data | |
| Chief Legal & People Officer | less than a year | no data | 0.00034% $ 734.5 | |
| Vice President of Marketing | no data | no data | no data | |
| Chief Commercial Officer | 2.8yrs | US$3.39m | 0.0066% $ 14.3k | |
| Senior Director of Investor Relations & Corporate Communications | no data | no data | no data |
3.3yrs
Average Tenure
54yo
Average Age
Experienced Management: GTHX's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.2yrs | US$3.25m | 0.28% $ 600.4k | |
| Member of Clinical Advisory Board | no data | US$456.29k | no data | |
| Independent Director | 8.7yrs | US$172.85k | 0.35% $ 765.5k | |
| Scientific & Clinical Advisor | no data | no data | no data | |
| Scientific & Clinical Advisor | no data | no data | no data | |
| Independent Director | 5.9yrs | US$162.85k | 0.030% $ 65.6k | |
| Independent Chairman of the Board | 5.7yrs | US$195.35k | 0.028% $ 59.4k | |
| Scientific & Clinical Advisor | no data | no data | no data | |
| Director | 1.8yrs | US$135.35k | 0% $ 0 | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Scientific & Clinical Advisor | no data | no data | no data | |
| Scientific & Clinical Advisor | no data | no data | no data |
5.7yrs
Average Tenure
66yo
Average Age
Experienced Board: GTHX's board of directors are considered experienced (5.7 years average tenure).